(Q46639344)

English

PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study

scientific article published on 5 August 2005

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16085692

PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16085692

1 reference

based on heuristic

inferred from title

pancreatic adenocarcinoma

1 reference

based on heuristic

inferred from title

metastatic pancreatic adenocarcinoma

1 reference

based on heuristic

inferred from title

Steven R Alberts

1

object named as

S R Alberts

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16085692

author name string

N R Foster

2

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16085692

R F Morton

3

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16085692

J Kugler

4

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16085692

P Schaefer

5

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16085692

M Wiesenfeld

6

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16085692

T R Fitch

7

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16085692

P Steen

8

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16085692

G P Kim

9

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16085692

S Gill

10

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16085692

publication date

5 August 2005

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16085692

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16085692

16

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16085692

10

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16085692

1654-1661

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16085692

Development of the proteasome inhibitor Velcade (Bortezomib).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI324

21 January 2018

Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI324

21 January 2018

Increased expression of NF-kappa B subunits in human pancreatic cancer cells

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI324

21 January 2018

26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI324

21 January 2018

Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI324

21 January 2018

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI324

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI324

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI324

21 January 2018

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI324

21 January 2018

Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI324

21 January 2018

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI324

21 January 2018

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI324

21 January 2018

Phase II trial of bortezomib for patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI324

21 January 2018

Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI324

21 January 2018

Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI324

21 January 2018

An analysis of variance test for normality (complete samples)

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI324

21 January 2018

Identifiers

10.1093/ANNONC/MDI324

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16085692

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16085692

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46639344&oldid=2123633308"